Cargando…
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
BACKGROUND: There is limited data on the efficacy of anti-programmed death 1 (PD-1) antibodies in patients (pts) with melanoma brain metastasis (BM), particularly those which are symptomatic. METHOD: We retrospectively assessed pts with melanoma BM treated with PD-1 antibodies, nivolumab and pembrol...
Autores principales: | Parakh, Sagun, Park, John J, Mendis, Shehara, Rai, Rajat, Xu, Wen, Lo, Serigne, Drummond, Martin, Rowe, Catherine, Wong, Annie, McArthur, Grant, Haydon, Andrew, Andrews, Miles C, Cebon, Jonathan, Guminski, Alex, Kefford, Richard F, Long, Georgina V, Menzies, Alexander M, Klein, Oliver, Carlino, Matteo S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518864/ https://www.ncbi.nlm.nih.gov/pubmed/28524161 http://dx.doi.org/10.1038/bjc.2017.142 |
Ejemplares similares
-
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014) -
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases
por: Killeen, S D, et al.
Publicado: (2007) -
Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015) -
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
por: Shen, B, et al.
Publicado: (2012) -
Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)